us everyone, thank morning, Good review Austin. you, Thank company you for for update fourth and and full results. joining quarter our Avadel's to and year XXXX
then XX. some will update launch provide progress, our XXXX. Tom provide our including results on Following metrics brief an Richard key through remarks, regarding my January will opening QX commentary our and review financial
session. conclude a question-and-answer will with We
arguments heard the now the Delaware, Avadel, we and aware, days ongoing this especially with past it's week awaiting As been were most Friday, closing a for likely in decision. of patent where trial jury's several you last are are busy
decision commentary this into dive general like I jury would to it release the potential LUMRYZ. take morning, trial impact the outcome, of updates relates we of or in press our we to provide don't launch still ongoing the before a the commercial some pending moment as to and the active patent in dispute.
Regardless in to business commercial our the announced current and expect patent So belief our
is the on or will decision provide dispute or not the litigation, trial, at questions the answer commentary an this any underlying this Given pending any active we time. further
transformational we as all will truly have provide initial on bring to community that this update worked appreciate Avadel, we we plan, understanding concludes, with the able and an the LUMRYZ and However, for the trial our a many matters, key execute for for final both monumental and were we have your FDA was have towards with which approval, launch narcolepsy company point.
XXXX been to year of when we years.
approximately has the which uptake In addition prescribers, received feedback launching month strong from we've the launch of been has last final since seen LUMRYZ X approval, unmatched and narcolepsy FDA June, achievement of LUMRYZ community. by patients among supported to within positive broader the
shortly. Our physicians, on momentum early progress of will this as throughout across by XXXX payers, being made which year, provide further Richard all continued into patients has demonstrated and launch details
us to expansion has LUMRYZ. a dedication the of the growth advancing decade-long LUMRYZ nearly to medicine space potential overall team's and to Our allowed and sleep continued for foundation build
our very clear. company as priorities crystal such, as a And remain
the and our and be promise foremost focus of opportunity. oxybate First the on potential our the and multibillion-dollar continues to strategy across executing launch delivering market on LUMRYZ
XXXX. the revenue are thus months the of we this momentum all the in LUMRYZ ended $XX have million fourth the the far. we December net evidenced and in by proud building for and quarter $XX.X million And X are is We accomplished XX,
the excessive daytime population. X, date ages expansion treatment for of opportunity application cataplexy our The to patients of for September into pediatric the the near-term potential accepted and LUMRYZ action with XXXX. an between narcolepsy second drug us and FDA provided Our X or supplemental of narcolepsy is our sleepiness XX new in
will the allow provide in at pediatric positive further approval caregivers believe LUMRYZ We narcolepsy impact to large. population community to and the
parents dosing dosing the regimen heard and LUMRYZ, challenges with about a potential directly population for to family.
We the twice-nightly if for this can children offer the also launch burden middle-of-the-night later the associated the We may that approval entire providing while with the the look from treatment year. pediatric of treatment approved, reducing have effective believe potential forward narcolepsy. create living and for burden an We
growth opportunity treatment there use at opinion the of many need in for field, key sleep LUMRYZ deep LUMRYZ When the bedtime is inertia idiopathic with associated the a or next significant with once for we're suffering the The leaders speaking for IH. pursuing hypersomnia from is IH. of
estimated the the to we also current IH be potentially patient options of to LUMRYZ. XX,XXX, meaningful diagnosed for indication, of population rare greater providing the uniquely if while LUMRYZ, approved suffering sleep future from the With an disorder, this upside those addition treatment believe than will value important for IH
are oxybate of LUMRYZ, bedtime second this lastly, bioequivalent as in a once profile product to sodium preclinical or of We for provide we with various when potential to reach enrolled.
And calendar at updates well to appropriate important the our provide planning target the half controlled IH advanced continuing no intend and is a stages are year, currently work initiate we we trial updates first formulation as randomized patient to milestones, in the intend well. including multicenter those is we a as and that development low
our market our made well sleep medicine are already In year a Coupled progress meaningful believe over billion we the of we positioned multibillion-dollar to year impact We and growth. offers LUMRYZ and and healthy the and opportunity. most within and closing, the that the LUMRYZ launch continue and a ahead. LUMRYZ.
I a are will potential accomplishments with to has share our am than the maintain during year, remain delivered believe reach this team importantly, of to the expand that with our highly market we we past this oxybate ended we view strong positioned in well advance significant of greater year space, progress proud our the to command continued a executing support position sheet balance that operations continue confident $X
over turn commercial that, for Richard? With the details Richard on I'll our to call progress.
